Atrial Fibrillation - Market Insights & Drugs Sales Forecast (AF) - 2020

  • ID: 3720539
  • Drug Pipelines
  • Region: Global
  • 70 Pages
  • DelveInsight
1 of 4
The Global Atrial Fibrillation Market Was $7.2 Billion in 2015 and Is Expected to Grow to $12.5 Billion by 2020

FEATURED COMPANIES

  • Bayer
  • Boehringer Ingelheim
  • Bristol-Myers Squib
  • Daiichi Sankyo
  • Janssen Pharmaceutica
  • MORE
The Atrial Fibrillation-Market Insights & Drugs Sales Forecast (AF) -2020 report provides an overview of the disease, epidemiology and global market trends for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan.

Coagulation is an important phenomenon of body to stop external bleeding but when clots are formed in blood vessels, it can be lethal. Blood clots in arteries can lead to heart attack and when formed in the blood vessels of brain can lead to stroke. Thus, anticoagulants are used to prevent the formation of blood clots in the body. Anticoagulants are proved to be a beneficial medication for the treatment of Atrial fibrillation, Deep Vein Thrombosis, Pulmonary Embolism and Stroke.

Key Coverage and Benefits:

- The report will help in developing business strategies by understanding the trends shaping and driving the global Atrial Fibrillation (AF) market.
- Identifying patient populations in the global Atrial Fibrillation (AF) market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the best opportunities for Atrial Fibrillation (AF) therapeutics in each of the markets covered.
- To understand the future market competition in the global Atrial Fibrillation (AF) therapeutics market and Insightful review of the key market drivers and barriers.

Scope of the Report:

- Report covers the disease overview including etiology, path physiology, symptoms, diagnosis, disease management and current treatment options.
- Marketed information including available prescription drugs, its patent and exclusivity details followed by drug sales till 2018.
- The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5, Japan and rest of the word from 2015-2020.
- It also provides Atrial fibrillation (AF) for United States, EU5 and Japan from 2015 and forecasted Market to 2020.

Note*: This report requires 2 business days to complete.

READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Bayer
  • Boehringer Ingelheim
  • Bristol-Myers Squib
  • Daiichi Sankyo
  • Janssen Pharmaceutica
  • MORE
Executive Summary
- Market Share of Anticoagulants in 2015 and 2020
- Worldwide Market Share of Anticoagulants in 2015
- Worldwide Market Share of Anticoagulants in 2020
Chapter 1 Anticoagulants Introduction
- Warfarin
- Low Molecular Weight Heparins
- New Oral Anticoagulants (NOAC)
Chapter 2 Atrial Fibrillation
- Disease Overview
- Epidemiology of Atrial Fibrillation
- Treatment Landscape
- Treatment Algorithm
- Treatment Goals
- Treatment Details
Chapter 3 Key Marketed Anticoagulants
- Novel Oral Anticoagulants Comparison
- Reversal Agents (Antidotes)
Chapter 4 Anticoagulants Market Assessment by AF
- Key Findings
- Global Anticoagulants Market Sales by Atrial Fibrillation (AF)
- Global Anticoagulants Market Share (%) in Atrial Fibrillation
Chapter 5 United States Anticoagulants Market Assessment by AF
- Key Findings
- United States Anticoagulants Market Sales by Atrial Fibrillation
- United States Anticoagulants Market Share (%) in Atrial Fibrillation
Chapter 6 Europe 5 Anticoagulants Market Assessment by AF
- Key Findings
- Europe 5 Anticoagulants Market Sales by Atrial Fibrillation
- Europe 5 Anticoagulants Market Share (%) in Atrial Fibrillation
Chapter 7 Japan Anticoagulants Market Assessment by AF
- Key Findings
- Japan Anticoagulants Market Sales by Atrial Fibrillation
- Japan Anticoagulants Market Share (%) in Atrial Fibrillation
Chapter 8 Xarelto (rivaroxaban) Drug Profile
- Product Profile
- Advantages & Disadvantages
- Efficacy of Xarelto
- Safety of Xarelto
- Side effects of Drugs
- Cost of Therapy
- Global Drug Sales
- Xarelto Historical Sales and Forecasted Sales (2011-2020)
- Global Drug Sales by indication
- Xarelto Historical Sales and Forecasted Sales (2011-2020) by AF
- Clinical Trials Information
- SWOT Analysis of Xarelto
Chapter 9 Pradaxa (dabigatran etexilate mesylate) Drug Profile
- Product Profile
- Advantages & Disadvantages
- Efficacy of Pradaxa
- Safety of Pradaxa
- Side effects of Drugs
- Cost of Therapy
- Global Drug Sales
- Pradaxa Historical Sales and Forecasted Sales (2011-2020)
- Global Drug Sales by indication
- Pradaxa Historical Sales and Forecasted Sales (2011-2020) by AF
- Clinical Trial Information
- SWOT Analysis of Pradaxa
Chapter 10 Eliquis(Apixaban) Drug Profile
- Product Profile
- Advantages & Disadvantages
- Efficacy and Safety of Eliquis
- Side effects of Eliquis
- Cost of Therapy
- Global Drug Sales
- Eliquis Historical Sales and Forecasted Sales (2011-2020)
- Global Drug Sales by indication
- Eliquis Historical Sales and Forecasted Sales (2011-2020) by AF
- Clinical Trial Information
- SWOT Analysis of Eliquis
Chapter 11 Savaysa (edoxaban tosylate) Drug Profile
- Product Profile
- Advantages & Disadvantages
- Efficacy of Savaysa
- Safety of Savaysa
- Side Effects of Savaysa
- Cost of Therapy
- Global Drug Sales
- Savaysa Historical Sales and Forecasted Sales (2011-2020)
- Global Drug Sales by indication
- Savaysa Historical Sales and Forecasted Sales (2011-2020) by AF
- Clinical Trial Information
- SWOT Analysis of Savaysa
Chapter 12 Market Drivers and Constraints
- Factors Driving the Market Growth
- Factors Constraining the Market Growth
- Consulting Services
Disclaimer

Tables

- Table 1 Key Marketed Anticoagulants
- Table 2 Comparison of NOACs & Warfarin
- Table 3 Global Anticoagulants Sales in Atrial Fibrillation 2011-2020 (USD MM)
- Table 4 Global Anticoagulants Sales in Atrial Fibrillation – 2015-2020 (USD MM)
- Table 5 US Anticoagulants Sales in Atrial Fibrillation 2011-2020 (USD MM)
- Table 6 US Anticoagulants Sales in Atrial Fibrillation - 2015-2020 (USD MM)
- Table 7 EU5 Anticoagulants Sales in Atrial Fibrillation 2011-2020 (USD MM)
- Table 8 EU5 Anticoagulants Sales in Atrial Fibrillation - 2015-2020 (USD MM)
- Table 9 Japan Anticoagulants Sales in Atrial Fibrillation 2011-2020 (USD MM)
- Table 10 Japan Anticoagulants Sales in Atrial Fibrillation - 2015-2020 (USD MM)
- Table 11 Xarelto Historical Sales and Forecasted Sales (2011-2020)(USD MM)
- Table 12 Xarelto Sales by Atrial Fibrillation (AF) (USD MM)
- Table 13 Xarelto, Clinical Trials by Zone, 2016
- Table 14 Pradaxa Historical Sales and Forecasted Sales (2011-2020)(USD MM)
- Table 15Pradaxa Sales by Atrial Fibrillation (AF) (USD MM)
- Table 16 Pradaxa, Clinical Trials by Zone, 2016
- Table 17 Eliquis Historical Sales and Forecasted Sales (2011-2020)(USD MM)
- Table 18Eliquis Sales by Atrial Fibrillation (AF) (USD MM)
- Table 19 Eliquis, Clinical Trials by Zone, 2016
- Table 20Savaysa Historical Sales and Forecasted Sales (2011-2020)(USD MM)
- Table 21SavaysaSales by Atrial Fibrillation (AF) (USD MM)
- Table 22 Savaysa, Clinical Trials by Zone, 2016

Figures
- Figure 1 Global Anticoagulants Sales in Atrial Fibrillation- 2011-2020
- Figure 2 Global Anticoagulants Market Share (%) in Atrial Fibrillation - 2011-2020
- Figure 3 US Anticoagulants Sales in Atrial Fibrillation- 2011-2020
- Figure 4 US Anticoagulants Market Share (%) in Atrial Fibrillation - 2011-2020
- Figure 5 EU5 Anticoagulants Sales in Atrial Fibrillation- 2011-2020
- Figure 6 EU5 Anticoagulants Market Share (%) in Atrial Fibrillation - 2011-2020
- Figure 7 Japan Anticoagulants Sales in Atrial Fibrillation- 2011-2020
- Figure 8 Japan Anticoagulants Market Share (%) in Atrial Fibrillation - 2011-2020
- Figure 9 Xarelto Historical Sales and Forecasted Sales (2011-2020) (USD MM)
- Figure 10 Xarelto Sales by Atrial Fibrillation (AF)(USD MM)
- Figure 11 Xarelto, Clinical Trials by Zone (%), 2016
- Figure 12 Pradaxa Historical Sales and Forecasted Sales (2011-2020) (USD MM)
- Figure 13 PradaxaSales by Atrial Fibrillation (AF)(USD MM)
- Figure 14 Pradaxa, Clinical Trials by Zone (%), 2016
- Figure 15 Eliquis Historical Sales and Forecasted Sales (2011-2020) (USD MM)
- Figure 16 EliquisSales by Atrial Fibrillation (AF)(USD MM)
- Figure 17 Eliquis, Clinical Trials by Zone (%), 2016
- Figure 18 SavaysaHistorical Sales and Forecasted Sales (2011-2020) (USD MM)
- Figure 19 SavaysaSales by Atrial Fibrillation (AF)(USD MM)
- Figure 20 Savaysa, Clinical Trials by Zone (%), 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
- Bayer
- Boehringer Ingelheim
- Bristol-Myers Squib
- Daiichi Sankyo
- Janssen Pharmaceutica
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll